Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC, Wang ZJ, Lin L, Li JL, Wang Y, Bai H, Hu XS, Liu YT, Hao XZ, Wang HY, Wan R, Wang X, Wang J.
Duan JC, et al. Among authors: wang x, wang zj, wang j, wang y, wang hy.
Invest New Drugs. 2019 Aug;37(4):731-737. doi: 10.1007/s10637-019-00735-1. Epub 2019 Feb 1.
Invest New Drugs. 2019.
PMID: 30706337
Clinical Trial.